A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of QLS2416 Injection in Participants With Autoimmune Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07906145

Title field or adapter rule

{'original_value': 'A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of QLS2416 Injection in Participants With Autoimmune Diseases', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:33.890782+00:00

Published At

2026-10-30T00:00:00+00:00

Record Updated At

2026-10-30

Source Retrieved At

2026-10-31T22:18:41.628690+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Systemic Lupus Erythematosus", "Rheumatoid Arthritis (RA)", "Primary Sj\u00f6gren\u0027s Syndrome (pSS)", "Systemic Sclerosis (SSc)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-30", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07906145"

protocolSection.identificationModule.officialTitle

"A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of QLS2416 Injection in Participants With Autoimmune Diseases"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Systemic Lupus Erythematosus (protocolSection.conditionsModule.conditions)
• Rheumatoid Arthritis (RA) (protocolSection.conditionsModule.conditions)
• Primary Sjögren's Syndrome (pSS) (protocolSection.conditionsModule.conditions)
• Systemic Sclerosis (SSc) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['QLS2416'], 'description': 'QLS2416 is a novel biologic agent administered via subcutaneous injection. Dose levels range from 0.025 mg to 6.0 mg.', 'name': 'QLS2416 Injection', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• QLS2416 Injection (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.